Compound from clams combats many common infections from parasites, finds study
A compound called tartrolon E, a byproduct of bacteria from shipworms, has been identified as researchers with the potential to fight and kill several parasites, including Cryptosporidium.
New research has revealed that a compound discovered in the gills of wood-eating clams could combat a group of parasites responsible for some of the world’s most common infections, including malaria, toxoplasmosis, cryptosporidiosis, theileriosis and babesiosis.
The study, conducted by scientists at Washington State University, US, identified tartrolon E, a byproduct of bacteria that help shipworms, a group of saltwater clams, digest the wood they eat.
According to the team, the compound, unlike any other, is proven to kill causal parasites for the aforementioned diseases.
“There are compounds that work against the individual parasites, but to find one that works against this entire group, that is what made this unique,” said Roberta O’Connor, an associate professor in Washington State University’s Veterinary Microbiology and Pathology unit and first author on the paper.
While there are already effective drugs for many of the parasites mentioned here, O’Connor said this group of parasites, called apicomplexans, readily develops drug resistance.
“Development of new, effective drugs against apicomplexan parasites is an ongoing need for human and veterinary medicine,” she said.
One of those parasites in need of a more effective remedy is Cryptosporidium. This waterborne zoonotic parasite is a major cause of diarrhoea in children, immuno-compromised patients and in newborn animals worldwide. The parasite infects millions of humans and agricultural animals annually.
In addition to killing this class of parasites in vitro, the researchers found that tartrolon E was able to kill Cryptosporidium in newborn mice. Beginning this summer, the scientists will test the compound against Cryptosporidium in lambs.
Currently, nitazoxanide is the only drug approved by the US Food and Drug Administration (FDA) to treat cryptosporidiosis.
“Nitazoxanide doesn’t work well for those [patients] who are immuno-compromised or malnourished and those are the people most vulnerable to Cryptosporidium,” O’Connor said. “Tartrolon E is obviously hitting some system that is common to these parasites. Even if this compound isn’t successful, if we can determine the mechanism, we will have identified a common drug target for all these parasites.”
The study was published in PLOS Pathogens.